Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395915 | 0.84 | CSNK2A2 (0.58) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL13660049 | 0.84 | CHRNA3 (0.71) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL1856137 | 0.83 | CHRNA3 (0.70) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL4173930 | 0.83 | CHRNA3 (0.70) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL1666395 | 0.83 | CSNK2A2 (0.90) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL7935547 | 0.82 | NPC1 (0.67) | NPY5R | |
| SCHEMBL1664964 | 0.82 | CSNK2A2 (0.88) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL6583002 | 0.81 | NPY5R (0.65) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| Iodide SCHEMBL2378107 | 0.80 | CSNK2A2 (0.62) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R | |
| SCHEMBL6960853 | 0.79 | CSNK2A2 (0.64) | CSNK2A2CSNK2A1CHRNA3KCNH2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | CSNK2A2 2674/4885CSNK2A1 2876/4885CHRNA3 3834/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | CSNK2A2 2173/4885CSNK2A1 2400/4885CHRNA3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.